Solara Active's debt-free target turned net debt-free without explanation
May call: 'internal target of making Solara debt-free by FY29'. July call: 'net debt-free...certain debt on the books'. Credibility question on the balance-sheet plan.
What's new
- Consolidated revenue ₹384 cr, up 20% YoY; EBITDA ₹63.5 cr, highest in 18 quarters.
- Base business grew 24% YoY to ₹307 cr, driven by new geographies and de-bottlenecking.
- Ibuprofen remained a drag with negative 12% EBITDA margin; loss guidance of ₹10-15 cr/quarter.
- Net debt fell 22% to ₹479 cr, helped by rights issue proceeds of ₹100 cr.
Themes from the call
Demand
Base-business growth of 24% YoY reflects order-book visibility and capacity de-bottlenecking; Ibuprofen volumes constrained by solvent shortages.
Margins
Consolidated EBITDA margin 17.0%. Base EBITDA margin around 25% targeted for FY27. Ibuprofen loss of ₹10-15 cr/quarter weighs on profitability.
Capital allocation
Debt target narrowed from debt-free to net debt-free by FY29. FY27 capex ₹55-60 cr, mostly de-bottlenecking. No greenfield projects.
Guidance watch
- Base-business revenue growth at least 10% YoY, currently trending above.
- Base-business EBITDA margin 25% ±1% for FY27.
- Ibuprofen negative EBITDA of ₹10-15 crores per quarter.
- Net debt below ₹450 cr (close to ₹440 cr) by March 2027.
- Strategic review of Ibuprofen, Vizag and Pondy expected by Q2 results or end-H1 FY27.
Risk flags
- Debt-free to net debt-free shift muddles deleveraging visibility.
- Ibuprofen strategic review delayed repeatedly; no clarity on capital recovery.
- West Asia disruption hurting input availability and costs; pass-through not fully offset.
- US tariff impact unquantified; commodity ibuprofen economics weak.
Key quotes
-
"We have an internal target of making Solara debt-free by FY '29."
— Solara management, May 2026 call -
"We have an internal aspiration of becoming net debt-free by FY29. Obviously, we will have certain debt on the books."
— Solara management, July 2026 call
The brief
Solara Active Pharma delivered its strongest EBITDA in 18 quarters this Q1, but a quieter shift in the debt target undermines the narrative. In May, management said it aimed to make Solara debt-free by FY29. In July, that target became net debt-free, with debt remaining on the books. The change was not explained.
The base business is genuinely improving. Revenue rose 24% to ₹307 crores, led by seeded products and capacity de-bottlenecking. Management guided for at least 10% growth and a 25% EBITDA margin for the base. Ibuprofen remains the weak link: negative 12% EBITDA margin, with losses of ₹10-15 crores a quarter. The strategic review for Ibuprofen and the mothballed Vizag plant is still pending.
Net debt fell 22% to ₹479 crores, but ₹100 crores of that came from a rights issue, not operations. The operating cash flow contribution was ₹35 crores. The new net-debt aspiration allows debt to stay on the books, a material downgrade from the May language. Anyone underwriting a cleaner balance sheet needs to ask whether the goalposts just moved.
The turnaround is real but incomplete. The base business is the driver. The Ibuprofen decision is the overhang. And the debt target is now a question of trust.
Solara's base business is healing, but the debt-goalpost shift turns a clean story into a credibility question.